BRIEF-WuXi Biologics Posts FY Revenue Of RMB18,675.4 Mln

Like
Comment
Favorite

BRIEF-WuXi Biologics Posts FY Revenue Of RMB18,675.4 Mln

Reuters03-25

March 25 (Reuters) - WuXi Biologics (Cayman) Inc 2269.HK:

FY REVENUE RMB 18,675.4 MILLION
FY GROSS MARGIN 41%
FY NET INCOME RMB 3,945.4 MILLION
FY GROSS PROFIT RMB 7,650.8 MILLION

Further company coverage: 2269.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

19:23
U.S. Appeals Court Allows Trump to Remove Democratic Members From Two Federal Labor Boards
19:18
US Federal Regulators Issue Preliminary Decision Supporting Rio Grande LNG Project's Environmental Approval -Document
19:08
Inogen Inc Shares Hit Session Low With Volume Pickup, Last Down 5.7% at $6.73
19:00
Rpt-Julong Holding Ltd - to List Class a Shares on Nasdaq Under 'Jlhl' - SEC Filing
19:00
the INX Digital Company Reports Q4 2024 and Annual Financial Results

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2522601825?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-25 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522601825","market":"nz","top_or_hot":-1,"title":"BRIEF-WuXi Biologics Posts FY Revenue Of RMB18,675.4 Mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-WuXi Biologics Posts FY Revenue Of RMB18,675.4 Mln</title></head><body><p><span>March 25 (Reuters)</span><span> - </span>WuXi Biologics (Cayman) Inc <span>2269.HK</span>:</p><ul><li><p>FY REVENUE RMB 18,675.4 MILLION</p></li><li><p>FY GROSS MARGIN 41%</p></li><li><p>FY NET INCOME RMB 3,945.4 MILLION</p></li><li><p>FY GROSS PROFIT RMB 7,650.8 MILLION</p></li></ul><p>Further company coverage: <span>2269.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-WuXi Biologics Posts FY Revenue Of RMB18,675.4 Mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-WuXi Biologics Posts FY Revenue Of RMB18,675.4 Mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-25 16:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-WuXi Biologics Posts FY Revenue Of RMB18,675.4 Mln</title></head><body><p><span>March 25 (Reuters)</span><span> - </span>WuXi Biologics (Cayman) Inc <span>2269.HK</span>:</p><ul><li><p>FY REVENUE RMB 18,675.4 MILLION</p></li><li><p>FY GROSS MARGIN 41%</p></li><li><p>FY NET INCOME RMB 3,945.4 MILLION</p></li><li><p>FY GROSS PROFIT RMB 7,650.8 MILLION</p></li></ul><p>Further company coverage: <span>2269.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nPLXCA4736:1","article_id":"2522601825","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522601825","pubTimestamp":1742892314,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-WuXi Biologics Posts FY Revenue Of RMB18,675.4 MlnMarch 25  - WuXi Biologics  Inc 2269.HK:FY REVENUE RMB 18,675.4 MILLIONFY GROSS MARGIN 41%FY NET INCOME RMB 3,945.4 MILLIONFY GROSS PROFIT RMB 7,650.8 MILLIONFurther company coverage: 2269.HK ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"简介-药明生物公布财年收入为人民币186.754亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":0.9},"content_text":"BRIEF-WuXi Biologics Posts FY Revenue Of RMB18,675.4 MlnMarch 25 (Reuters) - WuXi Biologics (Cayman) Inc 2269.HK:FY REVENUE RMB 18,675.4 MILLIONFY GROSS MARGIN 41%FY NET INCOME RMB 3,945.4 MILLIONFY GROSS PROFIT RMB 7,650.8 MILLIONFurther company coverage: 2269.HK ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}